Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

BACKGROUND: Polymyxin B sulfate and colistin, also known as colistimethate, have not been used for many years because less toxic antimicrobials are available. Gram-negative bacteria that are resistant to the aminoglycosides, beta-lactams, and fluoroquinolones are becoming more common. These bacteria are often susceptible to the polymyxins. OBJECTIVE: To present a review of the chemistry, antibacterial spectrum, dosing, pharmacokinetics, toxicity, and indications for polymyxin B sulfate and colistin. DATA SOURCE: A MEDLINE search (1966-1998) of the English-language literature was performed to identify primary literature on the polymyxins. Older citations ( 1949-1965) were identified through the bibliographies of these articles. STUDY SELECTION: All available reports of in vitro antibacterial activity, animal and clinical trials, and case reports were reviewed. DATA SYNTHESIS: The polymyxins are amphipathic molecules that interact with lipopolysaccharide in the bacterial outer membrane. They have potent antiendotoxic properties and antibacterial activity against Pseudomonas aeruginosa and many of the Enterobacteriaceae. Polymyxin B and colistin are usually given at a dose of 1.5-2.5 and 5 mg/kg/d, respectively, in two divided doses. Dosing must be altered in renal failure since the kidney is the primary route of elimination. Distribution into pleural fluid, joints, and cerebrospinal fluid is poor. Toxic effects involve the kidney and central nervous system. The polymyxins are recommended for serious systemic infections caused by gram-negative bacteria that are resistant to other agents. CONCLUSIONS: Polymyxin B sulfate and colistin have a role in the therapy of multidrug-resistant gram-negative bacterial infections.

This article has been cited by other articles:

				O. Cirioni, C. Silvestri, R. Ghiselli, F. Orlando, A. Riva, F. Mocchegiani, L. Chiodi, S. Castelletti, E. Gabrielli, V. Saba, et al. Protective effects of the combination of {alpha}-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection J. Antimicrob. Chemother., December 1, 2008; 62(6): 1332 - 1338. [Abstract] [Full Text] [PDF]

				A. Poudyal, B. P. Howden, J. M. Bell, W. Gao, R. J. Owen, J. D. Turnidge, R. L. Nation, and J. Li In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae J. Antimicrob. Chemother., December 1, 2008; 62(6): 1311 - 1318. [Abstract] [Full Text] [PDF]

				G. Cao, F. E. A. Ali, F. Chiu, A. P. Zavascki, R. L. Nation, and J. Li Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma J. Antimicrob. Chemother., November 1, 2008; 62(5): 1009 - 1014. [Abstract] [Full Text] [PDF]

				A. A Pastewski, P. Caruso, A. R Parris, R. Dizon, R. Kopec, S. Sharma, S. Mayer, M. Ghitan, and E. K Chapnick Parenteral Polymyxin B Use in Patients with Multidrug-Resistant Gram-Negative Bacteremia and Urinary Tract Infections: A Retrospective Case Series Ann. Pharmacother., September 1, 2008; 42(9): 1177 - 1187. [Abstract] [Full Text] [PDF]

				D. Landman, C. Georgescu, D. A. Martin, and J. Quale Polymyxins Revisited Clin. Microbiol. Rev., July 1, 2008; 21(3): 449 - 465. [Abstract] [Full Text] [PDF]

				M. S. Oliveira, G. V. B. Prado, S. F. Costa, R. S. Grinbaum, and A. S. Levin Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother., June 1, 2008; 61(6): 1369 - 1375. [Abstract] [Full Text] [PDF]

				W.-B. Wang, I-C. Chen, S.-S. Jiang, H.-R. Chen, C.-Y. Hsu, P.-R. Hsueh, W.-B. Hsu, and S.-J. Liaw Role of RppA in the Regulation of Polymyxin B Susceptibility, Swarming, and Virulence Factor Expression in Proteus mirabilis Infect. Immun., May 1, 2008; 76(5): 2051 - 2062. [Abstract] [Full Text] [PDF]

				A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215. [Abstract] [Full Text] [PDF]

				M. Krupovic, R. Daugelavicius, and D. H. Bamford Polymyxin B Induces Lysis of Marine Pseudoalteromonads Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3908 - 3914. [Abstract] [Full Text] [PDF]

				J. R. Lo-Ten-Foe, A. M. G. A. de Smet, B. M. W. Diederen, J. A. J. W. Kluytmans, and P. H. J. van Keulen Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3726 - 3730. [Abstract] [Full Text] [PDF]

				M. Meehl, S. Herbert, F. Gotz, and A. Cheung Interaction of the GraRS Two-Component System with the VraFG ABC Transporter To Support Vancomycin-Intermediate Resistance in Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2679 - 2689. [Abstract] [Full Text] [PDF]

				T. M. Arnold, G. N. Forrest, and K. J. Messmer Polymyxin antibiotics for gram-negative infections Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 819 - 826. [Abstract] [Full Text] [PDF]

				K. P Holloway, N. G Rouphael, J. B Wells, M. D King, and H. M Blumberg Polymyxin B and Doxycycline Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit Ann. Pharmacother., November 1, 2006; 40(11): 1939 - 1945. [Abstract] [Full Text] [PDF]

				J. Li, C. R. Rayner, R. L. Nation, R. J. Owen, D. Spelman, K. E. Tan, and L. Liolios Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 2946 - 2950. [Abstract] [Full Text] [PDF]

				M. H. Scheetz, K. M. Hurt, G. A. Noskin, and C. M. Oliphant Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens. Am. J. Health Syst. Pharm., July 15, 2006; 63(14): 1346 - 1360. [Abstract] [Full Text] [PDF]

				M. A. Campos, P. Morey, and J. A. Bengoechea Quinolones sensitize gram-negative bacteria to antimicrobial peptides. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2361 - 2367. [Abstract] [Full Text] [PDF]

				P. J. Bergen, J. Li, C. R. Rayner, and R. L. Nation Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1953 - 1958. [Abstract] [Full Text] [PDF]

				V. H. Tam, A. N. Schilling, G. Vo, S. Kabbara, A. L. Kwa, N. P. Wiederhold, and R. E. Lewis Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3624 - 3630. [Abstract] [Full Text] [PDF]

				A. Katragkou and E. Roilides Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin J. Clin. Microbiol., September 1, 2005; 43(9): 4916 - 4917. [Full Text] [PDF]

				S. K. Kasiakou, A. Michalopoulos, E. S. Soteriades, G. Samonis, G. J. Sermaides, and M. E. Falagas Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3136 - 3146. [Abstract] [Full Text] [PDF]

				A. L Quinn, J. P Parada, J. Belmares, and J P. O'Keefe Intrathecal Colistin and Sterilization of Resistant Pseudomonas aeruginosa Shunt Infection Ann. Pharmacother., May 1, 2005; 39(5): 949 - 952. [Abstract] [Full Text] [PDF]

				C. Martin, I. Ofotokun, R. Rapp, K. Empey, J. Armitstead, C. Pomeroy, A. Hoven, and M. Evans Results of an antimicrobial control program at a university hospital Am. J. Health Syst. Pharm., April 1, 2005; 62(7): 732 - 738. [Abstract] [Full Text] [PDF]

				L. A. Arroyo, A. Garcia-Curiel, M. E. Pachon-Ibanez, A. C. Llanos, M. Ruiz, J. Pachon, and J. Aznar Reliability of the E-Test Method for Detection of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii J. Clin. Microbiol., February 1, 2005; 43(2): 903 - 905. [Abstract] [Full Text] [PDF]

				R. N. Jones, T. R. Anderegg, J. M. Swenson, and The Quality Control Working Group Quality Control Guidelines for Testing Gram-Negative Control Strains with Polymyxin B and Colistin (Polymyxin E) by Standardized Methods J. Clin. Microbiol., February 1, 2005; 43(2): 925 - 927. [Abstract] [Full Text] [PDF]

				D. Berlana, J. M. Llop, E. Fort, M. B. Badia, and R. Jodar Use of colistin in the treatment of multiple-drug-resistant gram-negative infections Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 39 - 47. [Abstract] [Full Text] [PDF]

				M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061. [Abstract] [Full Text] [PDF]

				A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Borraz, and F. Gudiol Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model J. Antimicrob. Chemother., December 1, 2004; 54(6): 1085 - 1091. [Abstract] [Full Text] [PDF]

				R. Jain and L. H Danziger Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459. [Abstract] [Full Text] [PDF]

				M. E. Sobieszczyk, E. Y. Furuya, C. M. Hay, P. Pancholi, P. Della-Latta, S. M. Hammer, and C. J. Kubin Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections J. Antimicrob. Chemother., August 1, 2004; 54(2): 566 - 569. [Abstract] [Full Text] [PDF]

				J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, T. C. Smeaton, and K. Coulthard Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate J. Antimicrob. Chemother., May 1, 2004; 53(5): 837 - 840. [Abstract] [Full Text] [PDF]

				J. Li, K. Coulthard, R. Milne, R. L. Nation, S. Conway, D. Peckham, C. Etherington, and J. Turnidge Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis J. Antimicrob. Chemother., December 1, 2003; 52(6): 987 - 992. [Abstract] [Full Text] [PDF]

				J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, T. C. Smeaton, and K. Coulthard Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1766 - 1770. [Abstract] [Full Text] [PDF]

				B. W. Gunderson, K. H. Ibrahim, L. B. Hovde, T. L. Fromm, M. D. Reed, and J. C. Rotschafer Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 905 - 909. [Abstract] [Full Text] [PDF]

				H. Tsubery, I. Ofek, S. Cohen, M. Eisenstein, and M. Fridkin Modulation of the Hydrophobic Domain of Polymyxin B Nonapeptide: Effect on Outer-Membrane Permeabilization and Lipopolysaccharide Neutralization Mol. Pharmacol., November 1, 2002; 62(5): 1036 - 1042. [Abstract] [Full Text] [PDF]

				J. Li, R. W. Milne, R. L. Nation, J. D. Turnidge, K. Coulthard, and J. Valentine Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3304 - 3307. [Abstract] [Full Text] [PDF]

				A. Montero, J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol Efficacy of Colistin versus {beta}-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1946 - 1952. [Abstract] [Full Text] [PDF]

				J. M. Saugar, T. Alarcon, S. Lopez-Hernandez, M. Lopez-Brea, D. Andreu, and L. Rivas Activities of Polymyxin B and Cecropin A-Melittin Peptide CA(1-8)M(1-18) against a Multiresistant Strain of Acinetobacter baumannii Antimicrob. Agents Chemother., March 1, 2002; 46(3): 875 - 878. [Abstract] [Full Text] [PDF]

				L. Saiman, Y. Chen, S. Tabibi, P. San Gabriel, J. Zhou, Z. Liu, L. Lai, and S. Whittier Identification and Antimicrobial Susceptibility of Alcaligenes xylosoxidans Isolated from Patients with Cystic Fibrosis J. Clin. Microbiol., November 1, 2001; 39(11): 3942 - 3945. [Abstract] [Full Text] [PDF]

				A. C. Gales, A. O. Reis, and R. N. Jones Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines J. Clin. Microbiol., January 1, 2001; 39(1): 183 - 190. [Abstract] [Full Text]

				C. J. Thomas, N. Surolia, and A. Surolia Kinetic and Thermodynamic Analysis of the Interactions of 23-Residue Peptides with Endotoxin J. Biol. Chem., September 14, 2001; 276(38): 35701 - 35706. [Abstract] [Full Text] [PDF]